^
    Back
    Association details:
    Biomarker:AR positive
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:Ostarine (enobosarm) (Selective androgen receptor modulator, Androgen receptor modulator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase II Study of GTx024 in Women With Metastatic Breast Cancer

    Excerpt:
    ...Percentage of Subjects Treated With GTx024 With Clinical Benefit With AR Positive Breast Cancer...
    Trial ID:
    NCT01616758
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study. Add to Collection

    Published date:
    05/19/2021
    Excerpt:
    ...136 patients to evaluate the efficacy and safety of enobosarm in heavily pretreated women with AR+/ER+ MBC….Enobosarm is a novel oral selective AR activating agent in which a higher % AR staining correlates with a greater antitumor activity. By targeting and activating AR, enobosarm may represent a new hormone treatment approach for AR+/ER+ MBC.
    DOI:
    10.1200/JCO.2021.39.15_suppl.1020
    Trial ID:
    NCT02463032